{"entity":{"id":"nct07772024","kind":"trial","name":"Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 3 trial of Inobrodib run by CellCentric Ltd., now recruiting.","summary":"Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07772024 by CellCentric Ltd., with 450 participants planned, started 2026-08, primary completion expected 2029-11. Conditions recorded: Multiple Myeloma Refractory, Multiple Myeloma in Relapse. Interventions recorded: InoPd, Investigator's choice of SAT.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07772024","url":"https://clinicaltrials.gov/study/NCT07772024"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["inobrodib"],"companies":["cellcentric"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07772024","phase":"3","setting":"A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate Inobrodib in Combination With Pomalidomide and Dexamethasone Versus Standard Available Therapy in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"CellCentric Ltd.","enrolled":450,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07772024/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"inobrodib","kind":"drug","name":"Inobrodib","route":"/drugs/inobrodib/"}],"company":[{"id":"cellcentric","kind":"company","name":"CellCentric","route":"/companies/cellcentric/"}]}}